Browse NID1

Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix, basement membrane.
Domain PF12662 Complement Clr-like EGF-like
PF12947 EGF domain
PF07645 Calcium-binding EGF domain
PF07474 G2F domain
PF00058 Low-density lipoprotein receptor repeat class B
PF06119 Nidogen-like
PF00086 Thyroglobulin type-1 repeat
Function

Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell-extracellular matrix interactions.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0007160 cell-matrix adhesion
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0031589 cell-substrate adhesion
GO:0032835 glomerulus development
GO:0032836 glomerular basement membrane development
GO:0043062 extracellular structure organization
GO:0045785 positive regulation of cell adhesion
GO:0071711 basement membrane organization
GO:0072001 renal system development
GO:0072006 nephron development
Molecular Function GO:0001948 glycoprotein binding
GO:0005518 collagen binding
GO:0043236 laminin binding
GO:0043237 laminin-1 binding
GO:0043394 proteoglycan binding
GO:0050840 extracellular matrix binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005605 basal lamina
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
R-HSA-3000157: Laminin interactions
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NID1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NID1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NID1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.4390.019
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.480.264
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6740.676
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4050.386
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6980.789
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0330.992
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3330.581
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5610.778
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.2840.568
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8770.587
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8460.427
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.480.000243
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NID1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.78.2-4.50.671
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.710.2-6.50.425
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.2018.20.274
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NID1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NID1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NID1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NID1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NID1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NID1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNID1
Namenidogen 1
Aliases entactin; NID; nidogen (enactin); NID-1; enactin; Nidogen-1
Chromosomal Location1q43
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NID1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NID1.
ID Name Drug Type Targets #Targets
DB00013UrokinaseBiotechLRP2, NID1, PLAT, PLAU, PLAUR, PLG, SERPINA5, SERPINB2, SERPINE1, ......10